ArticleScientific reports2025
Negative-sense RNA virus nucleocapsid as a versatile platform for gene delivery, vaccine development, and antiviral screening.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assembly of the Linear Viral Nucleocapsid.Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viruses typically infiltrate host cells via specialized cellular receptors, a pivotal step that is challenging when suitable permissive cell lines or hosts are unavailable. Leveraging the unique internal replication machinery of negative-stranded (ns) RNA viruses, we demonstrate that purified nucleocapsid (NCs), their functional genomic templates, can directly initiate a complete viral life cycle upon intracellular delivery, bypassing conventional cell surface interaction. We successfully purified vesicular stomatitis virus (VSV) NCs, including those from a G-deleted pseudotyped variant (rVSV-ΔG-TFP). Exogenous delivery of these NCs into cells stimulated gene expression and generated infectious progeny virions (from full-length NCs). Critically, VSV-ΔG-TFP NCs, though self-amplifying, are inherently non-infectious, offering a safer, potentially more effective alternative for a vaccine development platform compared to live/attenuated viruses or mRNA-based systems. Furthermore, these NCs provide a secure method for transporting components of highly pathogenic nsRNA viruses (e.g., Nipah virus), acting as an inherent self-deactivating feature against accidental exposure. This study establishes NCs as a novel, intrinsically safer, and self-amplifying platform for antiviral screening, vaccine development, gene delivery, and biosafety in pathogen research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.